Spetzler David Baxley 4

What Happened
David Spetzler, President of Caris Life Sciences, was awarded 83,162 restricted stock units (RSUs) on March 6, 2026. The Form 4 reports the acquisition price as $0.00, reflecting an equity award (transaction code A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-06 (reported on Form 4 filed 2026-03-10).
• Reported price/acquisition: $0.00 (award of RSUs).
• Shares/units granted: 83,162 restricted stock units.
• Shares owned after transaction: not specified in the filing.
• Footnote: F1 — the award represents RSUs that will vest in accordance with the applicable grant agreement.
• Timeliness: Form 4 filed on 2026-03-10 covering the 3/6/2026 grant; filing appears to be within the standard two-business-day reporting window.

Context
RSU grants are compensation awards that typically convert to shares only as they vest per the grant agreement; they are not immediate purchases or sales and do not by themselves indicate a buy/sell decision in the market. The filing shows an award (A), not a cash transaction, and no immediate sale or exercise was reported.